Long term use of curcumin in two smoldering multiple myeloma patients
J Hematol Malign. 2013;3(1):18-23
|Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder. During the first 5 years, SMM has an overall risk of progression to multiple myeloma at a rate of 10% per year. Compared to monoclonal gammopathy of undetermined significance (MGUS), SMM is a more advanced pre-malignant condition.|
Due to highly unpredictable clinical course of SMM, early intervention involving reducing the abnormal protein load, the abnormal serum-free light chain ratio and the % plasma cell load is the method of approach.
Curcumin has been found to be effective against MGUS and SMM due to its anti-myeloma cell activity, which has been substantiated in several in vitro and in vivo studies. Researchers have also shown that oral Curcumin was effective against MGUS and SMM, in a select group of patients.
To study the long term use of Curcumin in two male patients with plasma cell dyscrasias.
Results and Discussion:
A significant improvement in a number of markers of disease activity with no side-effects from long term, high dose Curcumin therapy was witnessed. Hence, it is suggested that SMM patients may be benefited from long term Curcumin therapy without any toxicity.